Top 20 global biopharma firms see 1.7 per cent market cap growth to $3.7 billion in 2024 amid policy challenges Read more
AbbVie’s tavapadon holds potential to become prominent treatment in dopamine agonist market: GlobalData Read more
AbbVie’s $10.1 bn Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC investment surge: GlobalData Read more